Pharmaceutical giants fined record €444 million for ‘abusive practices’
Share article:
Share article:

Pharmaceutical giants fined record €444 million for ‘abusive practices’

Credit: Belga

Three major pharmaceutical companies were imposed a record fine of €444 million by the French competition authority on Wednesday.

The companies – Novartis, Roche and Genentech – are accused of “abusive practices” to “preserve” sales of a drug treating macular degeneration (AMD) to the detriment of a cheaper competing treatment. AMD is an eye disease that leads to vision loss.

“Genentech, Novartis and Roche have implemented a set of behaviours (abuse of collective dominant position) aimed at preserving the position and price of Lucentis, by curbing the off-label use of the cancer drug Avastin,” the authority said.

Lucentis is a treatment for AMD, an age-related retinal disease, developed by Genentech (which has capital ties with the Roche and Novartis groups).

However, doctors realised that another Genentech drug, the anti-cancer drug Avastin, had positive effects on AMD and began prescribing it even though it does not have market authorisation for this disease.

Avastin costs 30 times less than Lucentis: an injection of Avastin costs €30 to €40, compared with €1,161 for Lucentis.

Novartis markets Lucentis worldwide outside the United States and Roche markets Avastin.

Novartis “sought to thwart the initiatives of ophthalmologists who, in the context of their freedom to prescribe, decided to prescribe Avastin, outside the scope of their market authorisation, in ophthalmology,” the competition authority said.

“Novartis, Roche and Genentech were also sanctioned for having implemented a series of blocking measures and for having disseminated an alarming, and sometimes misleading, message to the public authorities on the risks associated with the use of Avastin for the treatment of AMD,” it added.

The authority considers that “the practices in question are particularly serious, as they occurred in the health sector, where competition is limited, and more specifically, in a context of public debate on the impact on social finances of the extremely high price of Lucentis,” which has been reimbursed at 100%.

Novartis will be fined €385,103,250, while Roche and Genentech will have to pay €59,748,726, amounting to a grand total of €444,851,976.

“We are very disappointed by the outcome of the Decision of the French Competition Authority and strongly refute the accusations of the FCA regarding alleged anti-competitive practices,” a spokesperson for Novartis said.

“Novartis firmly believes the company has acted appropriately and in compliance with all applicable regulations. Novartis intends to appeal the FCA Decision before the Court of Appeal in France.”

“For the Belgian investigation Novartis provided full and transparent collaboration to the Belgian Competition Authority. We firmly believe that we acted appropriately and in compliance with all applicable regulations in Belgium,” the spokesperson said. “We remain committed to improving the health of patients, in accordance with high ethical business standards and in compliance with laws and regulations that govern the manufacture of medicines and their safe use in patients.”

The Brussels Times

This story has been updated to include comment from Novartis.

Latest news

More women take police selection tests in Belgium
The selection tests to become a police inspector have more and more female participants, according to figures released by Interior Affairs Minister ...
‘Absurd’: all Brussels schools should have the same Covid rules
Several city councillors for education in Brussels are calling to abolish the "absurd" differences in coronavirus measures for Dutch-speaking and ...
Massive renovations for iconic venue in the heart of Brussels
Brussels concert hall Ancienne Belgique has announced plans to renovate the AB Café and the AB Salon and is looking for a contractor fit for the job. ...
Display of child’s room in Brussels raises awareness of foster families
An exhibit that features a fictitious child’s bedroom has been on display since Tuesday at the Place d'Armes in Namur, with the support of the ...
Test results show pupils have fallen behind in Flemish schools
Learning delays have been reported in almost all subject areas in Flanders since the start of the pandemic, a trend that continued in 2021, a ...
Belgium considers relaxing testing rules for UK travellers
At the next Consultative Committee meeting, Belgium will look into relaxing the testing and entry policy for travellers coming from the United ...
Jette libraries start giving plants away with books
Visitors to libraries in the Brussels municipality of Jette will soon be able to pick up a free plant along with a book, thanks to the new Plantotek ...
‘Do what you want, but do it as safely as possible,’ experts warn
As the daily number of new coronavirus infections exceeds 3,000 for the first time since May, infectious disease expert Erika Vlieghe and ...
‘We’re running dry’: Brussels teacher shortage reaches critical levels
The teacher shortage in Brussels is affecting schools across language borders, according to Brussels’ Minister for Multilingualism and Dutch ...
New coronavirus infections above 3,000 for first time since May
The number of people testing positive for coronavirus has skyrocketed to the highest rate since the start of May 2021. Between 9 and 15 October, ...
Belgium in Brief: Getting To The Airport
When I saw the news of plans for a tram line and cycle path to connect Brussels' outskirts to the airport, my first reaction was sheer joy.  Let ...
EU should invest €5 trillion in climate plan, says State Secretary for Economic Recovery
The European Union must invest €5 trillion in its climate plan over the next decade to "retain its credibility as a political project," according ...